Los puntos clave no están disponibles para este artículo en este momento.
Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.
Lv et al. (Thu,) studied this question.